Registration and prospectus / TriSalus Life Sciences, Inc. | Tables in SEC filings

TLSI TriSalus Life Sciences, Inc.

IPO registration

The following table sets forth information concerning the compensation of TriSalus’ directors for fiscal year 2023. Ms. Szela, our Chief Executive Officer, and Sean Murphy, our Chief Financial Officer, did not receive additional compensation for their service as a director in fiscal year 2023, and therefore are not included in the Director Compensation table below. All compensation paid to Ms. Szela and Mr. Murphy is reported above in the “Summary Compensation Table .” Additionally, prior to the closing of the Business Combination, none of the directors of MTAC received any cash compensation or equity awards for their service as a director of MTAC, and therefore, are not included in the Director Compensation table below to the extent such director’s service was terminated in connection with the closing of the Business Combination.


	Fees earned or			Option Awards
Name	paid in Cash		($)(1)(2)		Total ($)
Christopher C. Dewey	$	—	$	—	$	—
Robert H. Weiss	$	—	$	—	$	—
Karim Karti	$	—	$	—	$	—
Martin W. Roche, MD	$	—	$	—	$	—
Thierry Thaure	$	—	$	—	$	—
Manny Aguero	$	—	$	—	$	—
David Treadwell	$	—	$	—	$	—
Mats Wahlström	$	102,083	$	221,200	$	323,283
Andrew von Eschenbach	$	13,750	$	221,200	$	234,950
Anil Singhal	$	47,500	$	221,200	$	268,700
Arjun Desai	$	10,833	$	221,200	$	232,033
David J. Matlin	$	12,917	$	221,200	$	234,117
George Kelly Martin	$	25,000	$	221,200	$	246,200
Kerry Hicks	$	42,500	$	221,200	$	263,700


	Three Months Ended March 31,				Percent of Revenue
	2024		2023		2024			2023
Revenue	$	6,457	$	2,984		100.0	%	100.0	%
Cost of goods sold		971		662		15.0		22.2
Gross profit		5,486		2,322		85.0		77.8
Operating expenses:
Research and development		5,857		5,642		90.7		189.1
Sales and marketing		6,687		3,249		103.6		108.9
General and administrative		4,627		3,552		71.7		119.0
Loss from operations		(11,685)		(10,121)		(181.0)		(339.2)
Interest income		92		35		1.4		1.2
Interest expense		(3)		(5)		0.0		(0.2)
Loss on equity issuance		—		(1,465)		—		(49.1)
Extinguishment of tranche liability		—		881	$	(881)		(100.0)
Change in fair value of SEPA and warrant liabilities		2,521		2,421		39.0		81.1
Change in fair value of contingent earnout liability		(3,988)		—		(61.8)		—
Other expense, net		(153)		(19)		(2.4)		(0.6)
Loss before income taxes		(13,216)		(8,273)		(204.7)		(277.2)
Income tax expense		(3)		5		—		0.2
Net loss available to common stockholders	$	(13,219)	$	(8,268)		(204.7)	%	(277.1)	%
Deemed dividend related to Series B-2 preferred stock down round provision	$	—	$	(959)		—	%	(32.1)	%
Undeclared dividends on Series A preferred stock	$	(801)	$	—		(12.4)	%	—	%
Net loss attributable to common stockholders	$	(14,020)	$	(9,227)		(217.1)	%	(309.2)	%


	Year Ended
	2023		2022
Net cash used in operating activities	$	(50,045)	$	(32,313)
Net cash used in investing activities		(2,121)		(1,786)
Net cash provided by financing activities		54,629		13,462
Net increase / (decrease) in cash, cash equivalents and restricted cash	$	2,463	$	(20,637)


2024	$	88
2025		88
2026		88
2027		88
2028		88
Thereafter		687
	$	1,127


	December 31,			September 30,
	2023			2023
Current stock price	$	8.45		$	5.12
Expected share price volatility		65.0	%		65.0	%
Risk-free interest rate		3.9	%		4.6	%
Expected term (years)		4.6			4.9
Estimated dividend yield		—	%		—	%

Table search / Registration and prospectus / TriSalus Life Sciences, Inc.

64 results

Top filers

Top filing types

Recent filing years